Educational panel available for free via the Life Time App 6:00-7:30 p.m. CT CHANHASSEN, Minn., Sept. 23, 2024 /PRNewswire/ -- With interest in and demand for GLP-1 peptides continuing to explode, Life Time (NYSE: LTH) announced today that it will host a complimentary, informational livestreamed panel on September 25. The event is available to everyone via the complimentary Life Time App, and features insights from Life Time Chief Science Officer James LaValle, MIORA Medical Director Dr. Gregory Pippert and ...

Terns has a modest market cap of less than $800 million, and its possible upside could be massive. Goldman Sachs projects that the anti-obesity market will be worth as much as $100 billion by the end of the decade. It's currently dominated by a few big names in Eli Lilly and Novo Nordisk, but that can change drastically in the future. The best-selling glucagon-like peptide-1 (GLP-1) weight-loss treatments today are injections, but companies are working on pills which could be more attractive to patients, es ...

J Studios Introduction The telehealth company Hims & Hers (NYSE:HIMS) has seen its stock price range from under $6 to over $25 during the last 52 weeks. Since the stock price peaked in June, the stock has almost been cut in half. Back in May Hims surprised the market by announcing its affordable GLP-1 offering which immediately sent the stock soaring. However, recent news regarding Hims ability to continue with its GLP-1 offering beyond the temporary shortage has led to uncertainty around the stock. As of w ...

Omar Halawi/iStock via Getty Images I upgraded Becton, Dickinson and Company's (NYSE:BDX) to a 'Buy' rating in my previous article published in March 2024, arguing major growth challenges including Alaris pump and strong year-over-year comparables were fading away. I believe GLP-1 drug delivery could become a significant growth driver for the company in the near future. The company announced to acquire Edwards Lifesciences' (EW) Critical Care product group for $4.2 billion. I view the acquisition as value a ...

Company announcement – No. 44 / 2024 Zealand Pharma announces positive topline results from 13-week Phase 1b multiple ascending dose clinical trial with GLP-1/GLP-2 receptor dual agonist dapiglutide Placebo-adjusted reductions in body weight of up to a mean of 8.3% with dapiglutide after 13 weekly doses Dapiglutide treatment with doses up to 13 mg was assessed to be safe and well-tolerated with gastrointestinal adverse events consistent with the profile reported with other incretin-based therapies Higher do ...

TAMPA, Fla., Sept. 4, 2024 /PRNewswire/ -- Integrated Ventures Inc. (OTCQB: INTV), a holdings company, focused on e-commerce technology, digital assets and consumer-focused investments, is excited to announce (1) formation and launch of our second, fully funded, 100% owned subsidiary - MedWellDirect, LLC, Direct-ToConsumer (D2C) telemedicine solutions provider, mainly for weight loss and GLP-1 products and (2) acquisition of 51% stake in GetTrim.Com (TM), owned by Healthy Lifestyle USA – an innovative telem ...

The advent of GLP-1 weight-loss treatments has inadvertently underscored the importance of protein in mitigating muscle loss. While taking GLP-1 meds may be out of reach of many consumers due to exorbitant out-of-pocket costs and limited health insurance coverage, the popularity of high protein diets like keto or carnivore continues to gain popularity as a natural method to lose weight. Adding beef can reap rewards to a diet, but it's also proven to reap financial rewards for retail/wholesale sector restaur ...

Tim Platt/DigitalVision via Getty Images Thesis Viking Therapeutics (NASDAQ:VKTX) is a biotechnology company in the clinical stage focused on the discovery and development of novel treatments for metabolic and endocrinology disorders. Viking's most promising program is VK2735, a dual agonist (activator) of glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. VK2735 is aimed for the treatment of obesity, and it accounts for two formulations currently being tested ...

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - August 28, 2024) - Investorideas.com, a go-to investing platform covering health and wellness and biotech stocks issues a snapshot looking at news and developments for the global GLP-1 receptor agonist market, featuring new player in the market, Integrated Ventures, Inc. (OTCQB: INTV). Read the full article at Investorideas.com https://www.investorideas.com/News/2024/biotech/08280GLP-1.asp According to Research and Markets, The global GLP-1 ...

TAMPA, Fla. , Aug. 28, 2024 /PRNewswire/ -- Integrated Ventures, Inc. (OTCQB: INTV), a diversified portfolio holdings company, is excited to announce its strategic entry into the rapidly expanding health and wellness sector. The initial phase of this transition will be led by the newly established subsidiary, MedWell USA, LLC, which will serve as a B2B Procurement Agent for a variety of pharmaceutical products, with a particular focus on the booming medical weight loss and GLP-1 markets. MedWell USA will be ...